Are you Dr. Wang?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 8 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3400 Spruce St
8 Penn Tower
Philadelphia, PA 19104Phone+1 215-662-2789Fax+1 215-662-4500- Is this information wrong?
Summary
- Dr. Jingsong Wang, MD is a rheumatologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
Brigham and Women's HospitalFellowship, Rheumatology, 2001 - 2004
Medical College of GeorgiaResidency, Internal Medicine, 1999 - 2001
Xuzhou Medical CollegeClass of 1986
Certifications & Licensure
PA State Medical License 2006 - 2012
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Publications & Presentations
PubMed
- 91 citationsTranscription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13Antonios O. Aliprantis, Jingsong Wang, John W. Fathman, Raphael Lemaire, David M. Dorfman
Proceedings of the National Academy of Sciences of the United States of America. 2007-02-20 - 4 citationsBiomarkers in the development of novel disease-modifying therapies for osteoarthritis.Stephanie Parsons, Salvatore Alesci, Giora Z. Feuerstein, Jingsong Wang
Biomarkers in Medicine. 2008-12-12 - 96 citationsTranscription factor T-bet regulates inflammatory arthritis through its function in dendritic cells.Jingsong Wang, John W. Fathman, Geanncarlo Lugo-Villarino, Lucila Scimone, Ulrich H. von Andrian
The Journal of Clinical Investigation. 2006-02-01
Press Mentions
Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024September 14th, 2024- Harbour BioMed Completes First Subject Dosing in Phase I Trial of HBM7008October 21st, 2022
- Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United StatesOctober 20th, 2022
- Join now to see all
Professional Memberships
- Fellow
